Compare INBX & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBX | TSLX |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2024 | 2011 |
| Metric | INBX | TSLX |
|---|---|---|
| Price | $93.58 | $17.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $150.00 | $21.61 |
| AVG Volume (30 Days) | 331.5K | ★ 803.0K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.82% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 550.00 | N/A |
| 52 Week Low | $20.55 | $16.04 |
| 52 Week High | $155.29 | $25.17 |
| Indicator | INBX | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 53.72 |
| Support Level | $85.94 | $17.20 |
| Resistance Level | $96.12 | $18.05 |
| Average True Range (ATR) | 7.44 | 0.48 |
| MACD | 0.78 | 0.07 |
| Stochastic Oscillator | 33.00 | 65.95 |
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.